布地奈德、异丙托溴铵、α糜蛋白酶联合雾化吸入治疗AECOPD疗效观察  

Observation of efficacy on AECOPD with inhalation therapy combined budesonide, ipratropium bromide and α -Chymotrypsin

作　　者：孙红[1] 

机构地区：[1]江苏省苏州市吴中区长桥人民医院内科,江苏苏州215128

出　　处：《医院与医学》2014年第2期72-73,共2页Hospital and Medicine

摘　　要：目的研究联合布地奈德、异丙托溴铵、α糜蛋白酶氧气雾化吸入治疗AECOPD的疗效。方法40例AECOPD患者随机分为两组，每组20人。治疗组在常规治疗基础上联合布地奈德、异丙托溴铵、α糜蛋白酶氧气雾化吸入治疗，每日2次，共7天；对照组常规给予抗感染、止咳化痰、解痉平喘、吸氧等治疗。结果治疗组总有效率90％，对照组总有效率65％，两组比较有显著差异（P〈0．05）。结论联合布地奈德、异丙托溴铵、α糜蛋白酶氧气雾化吸入治疗AECOPD临床疗效好、安全可靠、副作用少。Objective To study the efficacy of acute exacerbation of chronic obstructive pulmonary disease （AECOPD）with inhalation therapy combined budesonide, ipratropium bromide and α-Chymotrypsin. Method Forty cases of AECOPD patients were randomly divided into two groups, 20 participants each. In the treatment group, conventional treatment and combined with budesonide, ipratropium bromide, α-chymotrypsin oxygen inhalation therapy were used, two times a day, a total of seven days; Control group routinely given antibiotics, medicine for cough and phlegm, antispasmodic and oxygen therapy. Results The total effective rate was 90% in the treatment group, and in control group was 65%, there was a significant difference between two groups,（P 〈0.05）. Conclusion The combined therapy of budesonide, ipratropium bromide and α-chymotrypsin oxygen inhalation in patients with AECOPD has good clinical efficacy, safety and reliability, and it has fewer side effects.

关 键 词：AECOPD 布地奈德 异丙托溴铵 Α糜蛋白酶 

分 类 号：R725.622.5[医药卫生—儿科]